OpenURL Connection Search

Select item for more details and to access through your institution.

Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.
Published in:
Leukemia (08876924), 2006, v. 20, n. 10, p. 1723, doi. 10.1038/sj.leu.2404356
By:
- Jehn, U.;
- Suciu, S.;
- Thomas, X.;
- Lefrère, F.;
- Muus, P.;
- Berneman, Z.;
- Marie, J-P.;
- Adamo, F.;
- Fillet, G.;
- Nobile, F.;
- Ricciuti, F.;
- Leone, G.;
- Rizzoli, V.;
- Montanaro, M.;
- Beeldens, F.;
- Fazi, P.;
- Mandelli, F.;
- Willemze, R.;
- de Witte, T.;
- Amadori, S.
Publication type:
Article
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.
Published in:
2005
By:
- Amadori, S.;
- Suciu, S.;
- Stasi, R.;
- Willemze, R.;
- Mandelli, F.;
- Selleslag, D.;
- Denzlinger, C.;
- Muus, P.;
- Stauder, R.;
- Berneman, Z.;
- Pruijt, J.;
- Nobile, F.;
- Cassibba, V.;
- Marie, J.-P.;
- Beeldens, F.;
- Baila, L.;
- Vignetti, M.;
- de Witte, T.
Publication type:
journal article
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK...
Published in:
Leukemia (08876924), 2003, v. 17, n. 5, p. 859, doi. 10.1038/sj.leu.2402897
By:
- Oosterveld, M;
- Suciu, S;
- Verhoef, G;
- Labar, B;
- Belhabri, A;
- Aul, C;
- Selleslag, D;
- Ferrant, A;
- Wijermans, P;
- Mandelli, F;
- Amadori, S;
- Jehn, U;
- Muus, P;
- Zittoun, R;
- Hess, U;
- Anak, O;
- Beeldens, F;
- Willemze, R;
- de Witte, T
Publication type:
Article

Found: 3

Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.

The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK...